Oppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potential
Oppenheimer updated its outlook on Tarsus Pharmaceuticals (NASDAQ:TARS), a $1.8 billion market cap biotechnology company, ...
Needham boosts Netflix stock target with upbeat outlook on ad revenue doubling in 2025
Needham analysts maintained a bullish stance on Netflix (NASDAQ:NFLX) shares, significantly raising the price target from $800 to $1,150, while reiterating a Buy rating. The upgrade follows Netflix's ...